How a Bone Marrow Transplant Works, Step by Step

A bone marrow transplant replaces a person’s diseased or damaged blood-forming cells with healthy stem cells, either from a donor or from the patient’s own body. The process unfolds over weeks to months, starting well before the transplant day itself and continuing long after. Each phase carries its own purpose and risks, and understanding the sequence helps demystify what is one of the most intensive treatments in modern medicine.

Two Types of Transplant, One Goal

Before any of the physical steps begin, the transplant team determines the type of procedure. In an allogeneic transplant, stem cells come from another person, either a relative or an unrelated volunteer. In an autologous transplant, a patient’s own stem cells are collected during a period of remission, stored, and returned after treatment. Each path has trade-offs. Allogeneic transplants carry the risk of the donor’s immune cells attacking the patient’s body, but they also bring a powerful anti-cancer benefit. Autologous transplants avoid that immune conflict entirely, but they lack the same cancer-fighting edge and carry a small risk that the returned cells still harbor disease. Early landmark work in the 1980s compared both approaches directly in leukemia patients, with allogeneic recipients receiving marrow from matched donors and autologous recipients getting their own marrow that had been treated to remove residual cancer cells.¹

Finding and Matching a Donor

For allogeneic transplants, donor selection is the single most consequential decision before treatment begins. The immune system identifies cells as “self” or “foreign” based on a set of proteins on cell surfaces. A transplant works best when the donor’s proteins closely match the recipient’s. The gold standard is a genetically identical sibling, but only about 30% of patients have one.² Everyone else needs an alternative: a matched unrelated donor found through a registry, a cord blood unit, or a half-matched (haploidentical) relative such as a parent or child.

A full match is typically assessed across ten markers, and a single mismatch at certain positions raises the odds of complications after transplant.² Haploidentical transplants, which share only half the markers, were once considered too dangerous because of high rates of graft rejection and immune attack on the recipient’s body. Modern techniques have largely overcome those barriers, making haploidentical donors a viable option for the vast majority of patients who lack a fully matched donor.³

When a haploidentical donor is used, the team also checks whether the patient has developed antibodies against the donor’s cell markers. If those antibodies are present, they can attack the incoming graft and cause it to fail. Patients are screened in advance, and donors carrying a targeted marker are avoided when possible.⁴

Collecting the Stem Cells

Once a donor is selected (or the patient’s own cells will be used), the next step is harvesting the stem cells. There are two main collection methods, and the choice affects both the donor’s experience and the transplant itself.

The traditional approach is a bone marrow harvest, where a surgeon draws liquid marrow directly from the back of the pelvic bone using a needle while the donor is under anesthesia. Donors typically experience skeletal pain, fatigue, and body aches afterward, with a median recovery time of a little over two weeks.⁵ The main risks are related to anesthesia, blood loss, and pain at the collection site.⁶

The more common modern method uses peripheral blood. Donors receive injections of a growth factor (G-CSF) for several days beforehand, which coaxes stem cells out of the marrow and into the bloodstream. Sometimes a drug called plerixafor is added; it works by blocking a molecular handshake that normally anchors stem cells inside the marrow, rapidly releasing them into the blood.⁷ When combined with G-CSF, the effect is stronger than either drug alone.⁸ The donor then sits for several hours connected to a machine that filters stem cells from the blood and returns the rest. Recovery from peripheral blood donation is faster, with a median of about one week, though donors experience bigger short-term drops in white blood cell and platelet counts compared to marrow donors.⁵

Conditioning: Clearing the Way

Before the new cells go in, the patient’s body needs preparation. This phase, called conditioning, involves high-dose chemotherapy, radiation, or both. It serves two purposes at once: destroying remaining cancer cells and suppressing the patient’s immune system enough that it won’t reject the incoming graft.

Conditioning regimens fall along a spectrum of intensity. At one end, myeloablative conditioning essentially wipes out the bone marrow. The resulting drop in blood cells is irreversible without a transplant to rescue the patient.⁹ At the other end, non-myeloablative conditioning causes only mild drops in blood counts and could theoretically be given without a transplant at all, though the transplant is still performed to establish a new immune system. In between sit reduced-intensity regimens, which cause significant but reversible drops in blood counts. The development of these gentler regimens opened transplantation to older adults and people with other health conditions who could not tolerate full-intensity treatment.¹⁰

Conditioning is physically grueling. Common side effects include severe nausea, painful mouth sores (mucositis), and liver damage. Some patients develop a condition where small blood vessels in the liver become blocked, and a rare but serious complication involves damage to tiny blood vessels throughout the body. These toxicities generally begin during conditioning and can persist for weeks to months after the transplant.¹¹

Day Zero: The Infusion Itself

After conditioning ends, there is usually a rest day before the transplant. The actual infusion day is called “Day Zero” in transplant terminology, and every day before it is counted as a minus number (Day −7, Day −1) while every day after is a plus number (Day +1, Day +30). The infusion looks surprisingly undramatic compared to what precedes it. The stem cells, whether fresh from a donor or thawed from cryopreservation, are delivered through an intravenous line in a process that can take anywhere from 30 minutes to a few hours.

The cells flow into the bloodstream much like a blood transfusion. Nurses monitor vital signs continuously during and after the infusion, watching for adverse reactions. In one detailed study of autologous transplants using cryopreserved cells, about seven out of ten procedures went smoothly, while the rest involved reactions like fever or other systemic changes requiring lab work and intervention.¹² Thawed cells in particular can carry a preservative (DMSO) that sometimes causes nausea, flushing, or a distinctive garlic-like taste and odor.

The Aplastic Phase: Waiting in Vulnerability

Once infused, the stem cells need time to travel to the bone marrow, settle in, and start producing new blood cells. In the meantime, the patient has essentially no functioning immune system and very few blood cells of any kind. This stretch, often called the aplastic or neutropenic phase, typically lasts two to four weeks and is the most dangerous period of the transplant.

Without white blood cells to fight infection, even bacteria that normally live harmlessly on the skin or in the gut can cause life-threatening bloodstream infections. In a study of 500 allogeneic transplant recipients, about a third developed at least one bloodstream infection during this phase. The death rate among those who developed infections was substantially higher than among those who did not, and deaths were frequently linked to invasive fungal infections rather than the bacteria themselves.¹³ Patients spend this time in isolation rooms, receive prophylactic antimicrobial medications, and often need transfusions of red blood cells and platelets to stay alive while waiting for the new marrow to take hold.

How the transplanted cells find their way to the bone marrow is itself a complex process. The cells circulate in the bloodstream and are attracted to the marrow cavity by chemical signals. Once there, they anchor to the marrow lining through a cascade of molecular interactions involving adhesion molecules and enzymes that help the cells burrow into the right niche.¹⁴

Engraftment: Signs of Success

Engraftment is the moment the transplanted stem cells begin producing new blood cells in meaningful numbers. The first reliable sign is a sustained rise in the neutrophil count, a type of white blood cell critical for fighting bacterial infections. Most transplant centers define engraftment as the first of three consecutive days when the neutrophil count stays above a threshold level, which usually happens somewhere between day +10 and day +28 depending on the cell source and conditioning regimen used.

Confirming engraftment goes beyond counting blood cells. Transplant teams run tests to determine what proportion of cells in the patient’s blood and marrow actually belong to the donor versus the recipient. These chimerism tests use genetic markers to distinguish donor from recipient cells. Modern sequencing-based approaches can detect recipient cells down to fractions of a percent, making it possible to catch very early signs that the graft is losing ground or that the original disease is returning.¹⁵

Sometimes engraftment fails. The patient’s surviving immune cells or antibodies may reject the graft, leaving the marrow empty. This risk is higher with mismatched donors, unrelated donors, and reduced-intensity conditioning regimens.¹⁶ Graft failure is a medical emergency that often requires a second transplant or an infusion of additional donor cells.

Rebuilding the Immune System

Even after the blood counts recover, the immune system remains deeply compromised. Rebuilding it is a slow, staged process. The body’s innate defenses, the front-line cells like granulocytes and natural killer cells, bounce back within weeks. But the adaptive immune system, the part responsible for targeted, learned responses to specific infections, takes much longer. B cells and T cells may reach normal numbers within the first few months, yet T-cell function in particular can remain impaired for years.¹⁷ This timeline means transplant recipients stay vulnerable to viral infections, reactivation of dormant viruses like cytomegalovirus, and other opportunistic pathogens for a prolonged period.¹⁸

Age plays a meaningful role here. Children tend to rebuild their T-cell populations more quickly and more completely than adults, likely because the thymus, the organ where T cells mature, shrinks and becomes less active starting in the late teenage years. Studies comparing immune recovery across age groups have found that adults experience more prolonged and severe T-cell deficits after transplant, regardless of donor type, suggesting the host’s own aging biology is a bottleneck.¹⁹

Graft-versus-Host Disease and the Graft-versus-Leukemia Tradeoff

In allogeneic transplants, the donor’s immune cells sometimes recognize the recipient’s body as foreign and mount an attack. This is graft-versus-host disease (GVHD), and it is one of the defining challenges of transplant medicine. Acute GVHD typically strikes within the first few months and targets the skin, gut, and liver.²⁰ Chronic GVHD can develop later and affect virtually any organ, sometimes resembling autoimmune diseases. It develops in roughly half to 70% of allogeneic transplant recipients within ten years.²¹

Here is where the biology gets interesting: the same immune attack that causes GVHD also targets leftover cancer cells. This graft-versus-leukemia effect is a major reason allogeneic transplants work as well as they do against blood cancers. The engrafting immune system actively hunts residual leukemia cells, and this effect can also be boosted after transplant by infusing additional donor white blood cells.²² Transplant teams walk a tightrope: too much immune suppression prevents GVHD but risks letting the cancer come back, while too little control can make GVHD lethal. Much of post-transplant management involves calibrating this balance through immunosuppressive drugs that are gradually tapered as the new immune system stabilizes.

Life After Transplant

Surviving the first hundred days is a milestone, but transplant recipients face years of follow-up care. The conditioning regimen’s damage to the body does not disappear. Long-term effects span nearly every organ system: secondary cancers, heart and blood vessel disease, thyroid problems, bone thinning, liver damage from the medications and the iron overload that comes with many transfusions. About 40–50% of patients develop lipid abnormalities that raise the risk of heart attack and stroke.²¹

Fertility is frequently affected. Gonadal dysfunction occurs in up to 92% of men and 99% of women after transplant, though the numbers vary based on the conditioning regimen, whether radiation was used, and the patient’s age at the time of treatment.²¹ For this reason, fertility preservation, through sperm banking or egg freezing, is discussed with patients before transplant whenever timing allows. Beyond physical complications, survivors contend with psychological challenges, financial strain, and difficulty returning to work or school.²³

Vaccination is another piece of the recovery puzzle. Because the transplant effectively resets the immune system, childhood immunizations lose their protection. Recipients typically restart a vaccination schedule from scratch, beginning several months after transplant once the new immune system is mature enough to respond.

Gene Therapy and the Changing Landscape

The basic architecture of bone marrow transplantation has been in use since the late 1950s, when E. Donnall Thomas and his colleagues performed the first human bone marrow transplants in leukemia patients, building on the discovery that marrow infusions could rescue animals from lethal radiation.²⁴ Decades of refinement in conditioning, donor matching, and supportive care have made transplant far safer, but the fundamental sequence of steps, wipe, infuse, wait, rebuild, remains recognizable.

The most transformative change on the horizon may come from gene therapy. Instead of replacing a patient’s stem cells with a donor’s, researchers can now collect a patient’s own stem cells, correct the genetic defect in a lab, and return the corrected cells. This approach is becoming a genuine alternative to allogeneic transplant for inherited immune disorders, hemoglobin diseases like sickle cell disease, and certain metabolic conditions, particularly when no well-matched donor is available.²⁵ Gene editing tools are also being paired with laboratory techniques that help edited stem cells maintain their primitive, regenerative properties during the correction process, improving the odds that the modified cells will engraft and produce healthy blood for the long term.²⁶ Gene-corrected autologous transplants still require conditioning to make room in the marrow, but they sidestep the entire donor-matching problem and eliminate the risk of GVHD, which could eventually reshape who needs a traditional allogeneic transplant and who does not.

1
PubMed. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia
2
PubMed Central. How to select the best available related or unrelated donor of hematopoietic stem cells?
3
Nature Reviews Clinical Oncology. Modern approaches to HLA-haploidentical blood or marrow transplantation
4
PubMed Central. Recommendations for Donor HLA Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
5
PubMed Central. Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Bone Marrow: A Prespecified Analysis from the Phase III BMT CTN Protocol 0201
6
PubMed Central. Supportive Care of Hematopoietic Stem Cell Donors
7
PubMed Central. Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
8
PubMed. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells
9
PubMed Central. Defining the intensity of conditioning regimens: working definitions
10
PubMed Central. A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
11
PubMed Central. Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation
12
Revista da Escola de Enfermagem da USP. Day zero of autologous cryopreserved hematopoietic stem cell transplantation: microcosting of care provided by senior nurses
13
Bone Marrow Transplantation. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection
14
PubMed. How do stem cells find their way home?
15
The Journal of Molecular Diagnostics. Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell Transplantation
16
PubMed Central. Graft failure after allogeneic hematopoietic cell transplantation
17
PubMed. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans
18
PubMed Central. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection
19
Blood. Comparison of Immune Reconstitution After Unrelated and Related T-Cell–Depleted Bone Marrow Transplantation: Effect of Patient Age and Donor Leukocyte Infusions
20
PubMed Central. Acute graft-versus-host disease
21
PubMed Central. Long-term follow-up after allogeneic stem cell transplantation
22
PubMed Central. Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia
23
PubMed Central. Long-term complications after hematopoietic cell transplantation
24
PubMed Central. E. Donnall Thomas, M.D. (1920–2012)
25
PubMed Central. Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives
26
Molecular Therapy. Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited human HSPCs